WTOP’s Matt Kaufax takes an even deeper dive into the Smithsonian Natural History Museum’s “Ocean Library” through DNA ...
LIGAND-AI is a flagship project of the Target 2035 initiative, funded by the Innovative Health Initiative, a public-private partnership (PPP) between the European Union and the European life science ...
By year-end 2028, submit new drug application evaluating cemsidomide and dexamethasone for potential accelerated approval in fourth line or later. In Q2 2026, initiate the Phase 1b trial of ...
Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...
Company enters into new agreement with the Gates Foundation to identify novel drug leads targeting tuberculosis and malaria and new agents for non-hormonal contraception. CHENGDU, China, Nov. 20, 2025 ...
Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities
WILMINGTON, Mass.--(BUSINESS WIRE)--$CRL #CDMO--Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc ...
Charles River Laboratories International, entered a strategic collaboration with X-Chem, a pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit ...
In this free webinar, gain insight into why the majority of DNA-encoded library (DEL) data has historically been ignored, and what is being missed. Attendees will learn how chemomic approaches ...
Despite the increasing popularity of targeted protein degradation as a therapeutic strategy, the majority of these drug discovery approach rely on just two E3 ligases, cereblon and VHL. The discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results